Citadel Advisors
BFRI icon

Citadel Advisors’s Biofrontera BFRI Stock Holding History

Citadel Advisors’s Portfolio BFRI Stock Details BFRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28,224
Closed -$22.6K – 12583
2025
Q1 		$22.6K Buy
+28,224
New +$29K ﹤0.01% 13058
2022
Q2 		– Sell
-2,525
Closed -$168K – 12882
2022
Q1 		$168K Buy
+2,525
New +$183K ﹤0.01% 11724

Other funds holding BFRI

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's BFRI Position: Q2 2025 in Review

Citadel Advisors sold out of Biofrontera (BFRI) in Q2 2025, closing a stake of 28,224 shares — an estimated $22.6K sold.

Citadel Advisors first reported a position in BFRI in Q1 2022 and held it in 2 quarters. The position peaked at $168K in Q1 2022. 10 funds tracked by Wall St. Rank hold BFRI as of Q2 2025.

  • Citadel Advisors reported no remaining Biofrontera position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 28,224 Biofrontera shares in Q2 2025, an estimated $22.6K.
  • Citadel Advisors first reported a position in Biofrontera in Q1 2022 and held it in 2 quarters.
  • Citadel Advisors's Biofrontera position peaked at $168K in Q1 2022.
  • 10 funds tracked by Wall St. Rank held Biofrontera as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.